News Conference News ESC 2025 AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC Todd Neale September 01, 2025
News Conference News NY Valves 2024 Long-term Mortality After TAVI Lower With DOACs vs VKAs Todd Neale June 06, 2024
News Daily News LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play Todd Neale March 15, 2024
News Daily News DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants Shelley Wood January 17, 2024
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Daily News Initiative Lowers Unnecessary Aspirin Use in Warfarin Users Todd Neale September 26, 2022
News Conference News CRT 2021 DOAC Use Increasing in Patients With Bioprosthetic Heart Valves Todd Neale March 08, 2021
News Daily News ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE Todd Neale December 22, 2020
News Daily News Thrombotic Events Frequent Among COVID-19 Patients in ICUs Michael O'Riordan October 27, 2020
News Daily News Uptick in Heparin-Induced Thrombocytopenia in COVID-19 Complicates Care Michael O'Riordan October 02, 2020
News Daily News Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects Michael O'Riordan July 13, 2020
News Daily News How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions Michael O'Riordan April 22, 2020
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Daily News High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin Shelley Wood March 08, 2019
News Conference News ISC 2019 Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects Todd Neale February 13, 2019
News Daily News Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks Todd Neale August 13, 2018
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ISC 2018 More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs Todd Neale January 27, 2018
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016